64Cu-DOTATATE PET for Neuroendocrine Tumors: a Prospective Head-to-Head Comparison with 111In-DTPA-octreotide in 112 Patients
| Autor: | Tina Binderup, Liselotte Højgaard, Jann Mortensen, Andreas Klaus Pfeifer, Eric von Benzon, Annika Loft, Palle Rasmussen, Anne Kiil Berthelsen, Dennis Ringkjøbing Elema, Peter Oturai, Andreas Kjaer, Ulrich Knigge, Seppo W. Langer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Biopsy Octreotide Neuroendocrine tumors Multimodal Imaging McNemar's test SDG 3 - Good Health and Well-being Stomach Neoplasms medicine Image Processing Computer-Assisted Organometallic Compounds Humans Radiology Nuclear Medicine and imaging Prospective Studies Receptors Somatostatin Neoplasm Metastasis Prospective cohort study Aged Aged 80 and over Tomography Emission-Computed Single-Photon PET-CT medicine.diagnostic_test business.industry Cancer Middle Aged Pentetic Acid medicine.disease Neuroendocrine Tumors Positron emission tomography Positron-Emission Tomography Female business Nuclear medicine Tomography X-Ray Computed medicine.drug |
| Zdroj: | Pfeifer, A K, Knigge, U, Binderup, T, Mortensen, J, Oturai, P, Loft, A, Berthelsen, A K, Langer, S W, Rasmussen, P, Elema, D R, von Benzon, E, Højgaard, L & Kjær, A 2015, ' 64Cu-DOTATATE PET for Neuroendocrine Tumors: a Prospective Head-to-Head Comparison with 111In-DTPA-octreotide in 112 Patients ', Journal of Nuclear Medicine, vol. 56, no. 6, pp. 847-854 . https://doi.org/10.2967/jnumed.115.156539 |
| DOI: | 10.2967/jnumed.115.156539 |
| Popis: | Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.METHODS:We prospectively enrolled 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin. All patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d. PET scans were acquired 1 h after injection of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan. Patients were followed for 42-60 mo for evaluation of discrepant imaging findings. The McNemar test was used to compare the diagnostic performance.RESULTS:Eighty-seven patients were congruently PET- and SPECT-positive. No SPECT-positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET. The diagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97% for both) were significantly better than those of (111)In-DTPA-OC (87% and 88%, respectively, P = 0.017). In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by (111)In-DTPA-OC.CONCLUSION:With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|